Biotech

Elicio Therapeutics is developing an off-the-shelf therapeutic mKRAS vaccine for pancreatic cancer. Phase 1 showed 84% T-cell response correlating with prolonged survival. Phase 2 data expected in H1 2026 will determine whether this approach can transform adjuvant therapy.

Abivax's obefazimod offers a novel oral approach to treat ulcerative colitis by activating miR-124 to downregulate specific pro-inflammatory pathways. Following impressive results in clinical Phase 3 studies, buyout rumors surrounding the French biotech are surging.

Despite impressive Phase I/II AMT-130 results, the FDA views current data as insufficient. Volumetric inclusion criteria may have raised concerns about potential bias. However, analysis indicates the thresholds were sufficiently inclusive, supporting the reported therapeutic effect.

The FDA’s new restrictive approach to rare disease therapies undermines confidence in regulatory consistency and impedes medical progress. After AMT-130 reduced disease progression by 75% in a phase I/II study, the agency’s reversal threatens to delay a breakthrough.

Dutch biotech uniQure's AMT-130 gene therapy shows 75% reduction in Huntington's progression, a breakthrough for this fatal neurodegenerative disease. Success opens path for treating Parkinson's, Alzheimer's or ALS with similar brain-delivered gene therapies.

Merck plans to acquire Verona Pharma for $10 billion, or $107 per share — a 363% gain for the Innovation & Freedom Portfolio.

Journey Medical's newly approved Emrosi™ outperformed Oracea® in two Phase III trials. If it captures a significant share of Oracea's $300m market, Journey could be significantly undervalued.